←Back to Expert Scholars
Translational Medicine / 转化医学TIL Therapy, Early Phase Trials
Abdul Rafeh Naqash
MD
🏢Stephenson Cancer Center, University of Oklahoma🌐USA
Assistant Professor of Medicine
30
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Abdul Rafeh Naqash is a phase I investigator focused on immunotherapy and TIL approaches in solid tumors including NSCLC. He designs and runs trials combining cell therapy with checkpoint blockade and novel agents. His translational research integrates genomics with cell therapy patient selection.
Share:
🧪Research Fields 研究领域
TIL therapy
early phase trials
immunotherapy
biomarkers
NSCLC
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Abdul Rafeh Naqash 的研究动态
Follow Abdul Rafeh Naqash's research updates
留下邮箱，当我们发布与 Abdul Rafeh Naqash（Stephenson Cancer Center, University of Oklahoma）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment